NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Sense NOT Woodford (cont): BETTER for NWBO et al:In many ways!

First, NEEDED House cleaning of Afford's snake like intrepretation of Woodford's Patient Capital Trust using derivatives (Options). Unlike other wheeler dealing businesses like real estate which I did lots of difficult and creative business deals; fund mgrs do NOT deviate from strictly regulated industry filings! since it IMPACTS in a much wider manner than a sole party in real estate.

Well here's the FACT as contained in Woodford Patient Capital Trust Prospectus Feb. 24, 2015 and on pg 29 from:https://woodfordfunds.com/wp-content/uploads/2015/02/woodford-patient-capital-trust-plc-prospectus.pdf

Hedging
The Company may use derivatives for the purposes of hedging any currency risk to which the Companymay be subject but will not use derivatives for investment purposes.

Additionally, from both an investment and portfolio strategy standpoint it makes more sense as well as better for not only the Institution, but also the NWBO marketplace that the 2.3 mln shs involve in Oct Put Option expiration (mentioned by AngeloFoca! which does raise the key question is this a truly BRAZEN Put Seller that is NAKED? since it clearly is not Woodford nor that of any of the tabulated institutional holders that own over a million shs:

Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
WOODFORD INVTMT MGT LLP 09/30/2015 20,461,392 3,740,000 22.37 126,042
GOLDMAN SACHS GROUP INC 06/30/2015 2,077,695 830,605 66.60 12,799
VANGUARD GROUP INC 06/30/2015 1,599,804 326,197 25.61 9,855
BLACKROCK FUND ADVISORS 06/30/2015 1,220,960 20,909 1.74 7,521

Read more: http://www.nasdaq.com/symbol/nwbo/institutional-holdings#ixzz3oDCFYk00

Also fitting My Point of View(MPOW) is this:
From Monthly Commentary from Woodford's Mitchell Fraser-Jones
14 September 2015,:
https://woodfordfunds.com/insight/august-2015/

Our US biotech holdings were also hit hard. The month’s largest detractor was Northwest Biotherapeutics, after rumours that the clinical trial of its DCVax-L oncology treatment had been suspended. The company has confirmed that the suspension related simply to the recruitment of new patients and was a temporary measure while regulatory information was submitted, in line with clinical protocols. The trial is continuing and we see nothing untoward in this development. Alkermes and Prothena sold off heavily too – again, we have no fundamental grounds for concern and were able to take advantage of the share price weakness.
Our main portfolio activity in August focused on taking advantage of the indiscriminate share price falls that accompanied the market panic towards the end of the month. This allowed us to add to a number of existing holdings at incredibly attractive valuation levels.

Although posted before, but in an much abbreviated form, it EXCLUDED the full commentary on ENTIRE US holdings: MPOV: Notice NO commentary of adding further to NWBO... UNLIKE in ALK or PRTA: "bought more on weakness". One can readily infer that because of their overweighted prominence as the single largest independent Institutional holder that Woodford funds would NOT be buying more pending a clarification /update from that August 22nd PR. Unless someone can point out that amongst Woodford's other holdings there are others in his portfolio holdings that are as prominent as NWBO that is MPOV.

MOREOVER no issue in Woodford's Patient Capital Trust can breech the 10% of Assets.

ALL HERE NOW HAVE TO DO A REVERSAL, which I mentioned mid August alomst 2 mos ago: THERE ARE OTHER INSTITUTIONs besides Woodford fortunately INTERESTED IN NWBO but haven't required a 13D SEC filing (less than 5%) and like to stay subrosa! and the next nasdaq instl update no earlier than ~ mid Nov